ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Medicare increases payments for oncology infusion and begins a one-year demonstration project that pays oncologists to assess the side effects of chemotherapy.

November 5, 2004

Ohio State Schedules Workshop On CCOP

February 5, 1982

ACS Approves 127 Cancer Programs; Total Now 994

March 18, 1983

DD Should Transfer Part of Breast Cancer $$ To NIH r Peer Distribution, Broder Says

December 4, 1992

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

November 25, 2011

Tarceva-Induced Rash Strongly Associated With Longer Survival, Sponsor Finds

July 27, 2007